Quick Answer
Processa Pharmaceuticals, Inc. reported Net Income Loss of -$13.56 million for the year ending 2025.
- Processa Pharmaceuticals, Inc. showed a decrease of -14.5% in Net Income Loss from 2024 to 2025.
- This data is from Processa Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Processa Pharmaceuticals, Inc.'s Net Income Loss has declined by 455.8%.
- Historical annual values: Fiscal year 2025: -$13.56 million | Fiscal year 2024: -$11.85 million | Fiscal year 2023: -$11.12 million | Fiscal year 2022: -$27.42 million | Fiscal year 2021: -$11.43 million | Fiscal year 2020: -$14.41 million | Fiscal year 2019: -$3.36 million | Fiscal year 2018: -$3.77 million | Fiscal year 2017: -$1.86 million | Fiscal year 2016: -$1.92 million | Fiscal year 2015: -$3.35 million | Fiscal year 2014: -$4.53 million | Fiscal year 2013: -$3.07 million | Fiscal year 2012: -$2.44 million.
- Data sourced from SEC EDGAR public filings as of June 22, 2026.
Last verified: